Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

New England Journal of Medicine

Volumn 353, Issue 4, 2005, Pages 362-368

  Van Assche, Gert ^a   Van Ranst, Marc ^b   Sciot, Raf ^a   Dubois, Bénédicte ^a   Vermeire, Séverine ^a   Noman, Maja ^a   Verbeeck, Jannick ^b   Geboes, Karel ^a   Robberecht, Wim ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BETA1A INTERFERON; BUDESONIDE; CORTICOSTEROID; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; PHENYTOIN; VIRUS DNA; ALPHA4 INTEGRIN;

ADULT; ANEMIA; ARTICLE; BRAIN INJURY; BRAIN SURGERY; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE SEVERITY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; ILEUM RESECTION; JC VIRUS; LABORATORY TEST; LYMPHOCYTOPENIA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SEIZURE; SERUM; SOMNOLENCE; SYMPTOM; TREATMENT FAILURE; VIRUS LOAD; ASTROCYTOMA; BLOOD; BRAIN; BRAIN TUMOR; CHEMICALLY INDUCED DISORDER; DIAGNOSTIC ERROR; FATALITY; GENETICS; GENOTYPE; IMMUNOLOGY; ISOLATION AND PURIFICATION; LEUKOCYTE COUNT; LEUKOENCEPHALOPATHY; MIDDLE AGED; OPPORTUNISTIC INFECTION; PATHOLOGY; VIROLOGY;

ANTIBODIES, MONOCLONAL; ASTROCYTOMA; BRAIN; BRAIN NEOPLASMS; CROHN DISEASE; DIAGNOSTIC ERRORS; DNA, VIRAL; FATAL OUTCOME; GENOTYPE; HUMANS; INTEGRIN ALPHA4; JC VIRUS; LEUKOCYTE COUNT; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; VIRAL LOAD;

EID: 22844445587     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa051586     Document Type: Article

References (24)

1. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
2. 4-integrin in active Crohn's disease. Gastroenterology 2001;121:268-74.
3. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32.
4. Biogen Idec and Elan announce voluntary suspension of TYSABRI. Press release of Elan-Biogen, Dublin, February 28, 2005. (Accessed July 1, 2005, at http://www.elan.com/News/full.asp?ID=679361.)
5. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74.
6. Herman J, Van Ranst M, Snoeck R, Beuselinck K, Lerut E, Van Damme-Lombaerts R. Polyomavirus infection in pediatric renal transplant recipients: evaluation using a quantitative real-time PCR technique. Pediatr Transplant 2004;8:485-92.
7. Jobes DV, Chima SC, Ryschkewitsch CF, Stoner GL. Phylogenetic analysis of 22 complete genomes of the human polyomavirus JC virus. J Gen Virol 1998;79:2491-8.
8. Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leuko-encephalopathy: a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958;81:93-111.
9. Richardson EP Jr. Progressive multifocal leukoencephalopathy. N Engl J Med 1961;265:815-23.
10. Holman RC, Janssen RS, Buehler JW, Zelasky MT, Hooper WC. Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology 1991;41:1733-6.
11. Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int 2005;17:658-65.
12. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973;127:467-70.
13. Ferrante P, Caldarelli-Stefano R, Omodeo-Zorini E, et al. Comprehensive investigation of the presence of JC virus in AIDS patients with and without progressive multifocal leukoencephalopathy. J Med Virol 1997;52:235-42.
14. Koralnik IJ, Boden D, Mai VX, Lord CI, Letvin NL. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 1999;52:253-60.
15. Wei G, Liu CK, Atwood WJ. JC virus binds to primary human glial cells, tonsillar stromal cells, and B-lymphocytes, but not to T lymphocytes. J Neurovirol 2000;6:127-36.
16. Ciricillo SF, Rosenblum ML. Use of CT and MR imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients. J Neurosurg 1990;73:720-4.
17. Richardson EP Jr, Webster HD. Progressive multifocal leukoencephalopathy: its pathological features. Prog Clin Biol Res 1983;105:191-203.
18. Dubois V, Moret H, Lafon ME, et al. JC virus genotypes in France: molecular epidemiology and potential significance for progressive multifocal leukoencephalopathy. J Infect Dis 2001;183:213-7.
19. Agostini HT, Ryschkewitsch CF, Singer EJ, Baumhefner RW, Stoner GL. JC virus type 2B is found more frequently in brain tissue of progressive multifocal leukoencephalopathy patients than in urine from controls. J Hum Virol 1998;1:200-6.
20. von Andrian UH, Mackay CR. T-cell function and migration. N Engl J Med 2000;343:1020-34.
21. Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 2004;17:365-70.
22. Koralnik IJ, Du Pasquier RA, Letvin NL. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol 2001;75:3483-7.
23. Milner R, Campbell IL. Developmental regulation of beta1 integrins during angiogenesis in the central nervous system. Mol Cell Neurosci 2002;20:616-26.
24. Kloss CU, Werner A, Klein MA, et al. Integrin family of cell adhesion molecules in the injured brain: regulation and cellular localization in the normal and regenerating mouse facial motor nucleus. J Comp Neurol 1999;411:162-78.